We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BARDA Awards $51.9 Million Contract to DNAe
News

BARDA Awards $51.9 Million Contract to DNAe

BARDA Awards $51.9 Million Contract to DNAe
News

BARDA Awards $51.9 Million Contract to DNAe

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BARDA Awards $51.9 Million Contract to DNAe "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DNA Electronics (‘DNAe’), the inventors of semiconductor-based next- generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for blood stream infections, announce s that t he Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) has awarded the Company a contract worth up to $51.9 million to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza. 

Genomic information derived from DNA sequencing is transforming many areas of medicine. This is the first NGS platform supported by BARDA, with game-changing potential in the diagnosis and treatment of infectious diseases. 

The contract for the project entitled PISCES (Pathogen Identification from Specimen, via Capture Extraction and Sequencing) will enable DNAe to complete the development and validation of its ground -¬‐ breaking Genalysis® platform and support a series of application s to the U.S. Food and Drug Administration for marketing clearance. 

The Genalysis® platform will combine the ability to sequence the DNA of the infectious organism, in a sealed microchip based system, direct from clinical specimen, with analysis that enables actionable identification of the disease agent within a few hours, a key requirement in the effective treatment of infectious diseases. 

Advertisement